Fennec Pharmaceuticals Inc. (FENC) Stock Price & Analysis

Fennec Pharmaceuticals Inc. (FENC) is trading at USD 13.36, down 1.62% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.

FENC last closed at USD 13.36; today's session has ranged USD 13.04–13.85 on volume of 517,266 shares. Market capitalization is —, with a 52-week range of USD 5.65–13.85 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.

Also available as compact Markdown for AI agents: nexqual.com/FENC.md

Key facts (FENC)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FENC)

USDFY2021FY2022FY2023FY2024FY2025TTM
Revenue—$1.5M$21.3M$47.5M$44.6M$66.4M
Gross profit—$1.4M$20.0M———
Operating income-$17.2M-$22.6M-$12.8M$2.6M-$6.3M$3.7M
Net income-$17.3M-$23.7M-$16.0M-$436K-$9.7M$2.0M
EPS (diluted)-$0.67-$0.90-$0.60-$0.02-$0.34—
Gross margin—94.4%94.1%———
Operating margin—-1471.6%-60.1%5.4%-14.1%5.6%
Net margin—-1544.9%-75.5%-0.9%-21.8%3.1%
Revenue growth——+1284.5%+123.7%-6.1%—
Cash + short-term investments$21.1M$23.8M$13.3M$26.6M$36.8M—
Total debt$5.0M$24.9M$30.9M$19.3M——

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (FENC)

Analysts (FENC)

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-09-09HC Wainwright & Co.ReiteratedBuy$16
2026-08-12B. Riley SecuritiesTarget raisedBuy$16 → $18
2026-08-12WedbushTarget raisedOutperform$13 → $16

Total return (dividends reinvested) (FENC)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return+52.7%+36.0%
S&P 500 (SPY)+11.9%+66.7%
Per year+52.7%+6.3%
Volatility (annualized)66.0%62.1%
Max drawdown-35.8% (Feb 2026→Mar 2026)-64.4% (Dec 2023→Nov 2024)

Dividends (FENC)

FENC paid no cash dividend in the last five years.

Short interest (FENC)

454,453 shares sold short, 1.49% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 513,287 shares (-11.5%). Days to cover: 3.6 (short shares ÷ average daily volume).

FENC earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
Mar 24, 2026Quarter ended Dec 31, 2025−$0.10$0.04Miss −$0.14-17.2%
Mar 10, 2025————-7.0%
Mar 25, 2024————+0.8%
Nov 7, 2023————-4.3%
Aug 4, 2023————+1.4%

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

FENC recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 2026Schedule 13G/ASolas Capital Management, LLC, FREDERICK TUCKER GOLDEN: 4.1% of shares, passive 5%+ holder (amended)
Nov 16, 2026Schedule 13G/ASonic Fund II, L.P., Sonic GP LLC: 4.5% of shares, passive 5%+ holder (amended)
Nov 12, 202610-QQuarterly report · period ended Sep 30, 2026
Oct 19, 2026Schedule 13G/AOrin Hirschman, AIGH Capital Management LLC: 7.1% of shares, passive 5%+ holder (amended)
Sep 17, 20268-KOther material event
“On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 8.01, including Exhibit 99.1 attached hereto, shall not be…”
Aug 14, 2026Schedule 13G/ASouthpoint Master Fund, LP, Southpoint Capital Advisors LP: 0.0% of shares, passive 5%+ holder (amended)
Aug 14, 2026Schedule 13G/ASolas Capital Management, LLC, FREDERICK TUCKER GOLDEN: 5.4% of shares, passive 5%+ holder (amended)
Aug 13, 202610-QQuarterly report · period ended Jun 30, 2026
Aug 13, 2026Schedule 13G/ARosalind Advisors, Inc., SALAMON STEVEN A J: 9.6% of shares, passive 5%+ holder (amended)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

FENC suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
PartnerNorgine Pharma UK“In March 2024, we announced that we entered into an agreement with Norgine, a leading European specialist pharmaceutical company.”

Quoted from the company's 10-K filed Mar 27, 2026.

FENC analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$0.18$0.14+28.5%$22.1M4
Next quarter (ends Mar 2027)$0.13$0.11+18.2%$22.5M3
Current fiscal year (ends Dec 2026)$0.41$0.33+21.3%$74.7M4
Next fiscal year (ends Dec 2027)$1.02$0.95+7.6%$106.7M5

FENC options: expected move

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262348.7%±25.4%
Feb 19, 20279399.1%±42.6%

30-day implied volatility 128.7% vs 69% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 20:43 UTC)

PriceUSD 13.36
Change▼ 1.62% (down)
Previous CloseUSD 13.36
OpenUSD 13.36
Day RangeUSD 13.04 – 13.85
52-Week RangeUSD 5.65 – 13.85
Volume517,266 shares
Market Cap—
ExchangeNCM

Technical Analysis (FENC)

Nexqual's technical model rates FENC "BUY" based on 5 bullish and 3 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.

Overall SignalBUY
RSI (14)70.95 (overbought)
vs SMA50Above (USD 10.71)
MACD0.56 (positive)

Earnings (FENC)

Next Earnings Date2026-11-12
EPS EstimateUSD 0.19
Revenue Estimate$22.07M

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD 0.12 vs est 0.11 ▲ beat
2026-06-30USD 0.05 vs est 0.02 ▲ beat
2026-03-31USD 0.01 vs est -0.02 ▲ beat
2025-12-31USD -0.1 vs est 0.04 ▼ miss

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financials & Fundamentals (FENC)

Total Revenue$66.37M
Revenue Growth (latest quarter, YoY)+57.30%
Gross Margin+94.13%
Operating Margin+5.60%
Profit Margin+3.05%
ROE+9.07%
Current Ratio6.11
Total Cash$48.68M
Total Debt$0

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financial Health Score (FENC)

Nexqual rates Fennec Pharmaceuticals Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.

GrowthStrong — Revenue +71% (last 4 quarters to Sep 2026 vs the 4 before, SEC)
ProfitabilityWeak — Small revenue base — building scale
Balance SheetMixed — $49M cash, no debt
Cash FlowWeak — Operating cash flow -$12M (FY ended Dec 2025, 10-K)
EfficiencyWeak — ROE 4%, ROA 2.4% (last 4 quarters, SEC)

Ownership (FENC)

Insider Ownership+13.93%
Institutional Ownership+54.97%
Shares Outstanding35.31M
Float20.08M
Short % of Float+1.49%

Source: Nexqual, November 18, 2026 at 20:43 UTC.

From Fennec Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 98.14▲ 1.38%
BLTEBelite Bio, IncUSD 157.14▼ 0.37%
IBRXImmunityBio, Inc.USD 6.71▲ 7.19%
ORKAOruka Therapeutics, Inc.USD 95.92▼ 0.42%
IMVTImmunovant, Inc.USD 33.3▲ 0.27%
CGONCG Oncology, Inc.USD 79.9▲ 1.22%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt